 | • レポートコード：MRC2312MG13507 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：化学＆材料 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界のGLP-1ペプチド原薬市場規模と予測を収録しています。・世界のGLP-1ペプチド原薬市場：売上、2018年-2023年、2024年-2029年 ・世界のGLP-1ペプチド原薬市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のGLP-1ペプチド原薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「セマグルチド」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 GLP-1ペプチド原薬のグローバル主要企業は、CPC Scientific、 Novo Nordisk、 Teva Pharmaceutical Industries Ltd、 JYMedtech、 Zhejiang Peptites Biotech、 Shengnuo Biotechnology、 Suzhou Tianma Pharmaceutical、 SINOPEP、 WuXi AppTec、 HYBIO Pharmaceuticalなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、GLP-1ペプチド原薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のGLP-1ペプチド原薬市場：タイプ別、2018年-2023年、2024年-2029年 世界のGLP-1ペプチド原薬市場：タイプ別市場シェア、2022年 ・セマグルチド、リラグルチド、チルポチド 世界のGLP-1ペプチド原薬市場：用途別、2018年-2023年、2024年-2029年 世界のGLP-1ペプチド原薬市場：用途別市場シェア、2022年 ・糖尿病、肥満、その他 世界のGLP-1ペプチド原薬市場：地域・国別、2018年-2023年、2024年-2029年 世界のGLP-1ペプチド原薬市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるGLP-1ペプチド原薬のグローバル売上、2018年-2023年 ・主要企業におけるGLP-1ペプチド原薬のグローバル売上シェア、2022年 ・主要企業におけるGLP-1ペプチド原薬のグローバル販売量、2018年-2023年 ・主要企業におけるGLP-1ペプチド原薬のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 CPC Scientific、 Novo Nordisk、 Teva Pharmaceutical Industries Ltd、 JYMedtech、 Zhejiang Peptites Biotech、 Shengnuo Biotechnology、 Suzhou Tianma Pharmaceutical、 SINOPEP、 WuXi AppTec、 HYBIO Pharmaceutical ************************************************************* ・調査・分析レポートの概要 GLP-1ペプチド原薬市場の定義 市場セグメント 世界のGLP-1ペプチド原薬市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のGLP-1ペプチド原薬市場規模 世界のGLP-1ペプチド原薬市場規模：2022年 VS 2029年 世界のGLP-1ペプチド原薬市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのGLP-1ペプチド原薬の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のGLP-1ペプチド原薬製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：セマグルチド、リラグルチド、チルポチド GLP-1ペプチド原薬のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：糖尿病、肥満、その他 GLP-1ペプチド原薬の用途別グローバル売上・予測 ・地域別市場分析 地域別GLP-1ペプチド原薬市場規模 2022年と2029年 地域別GLP-1ペプチド原薬売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） CPC Scientific、 Novo Nordisk、 Teva Pharmaceutical Industries Ltd、 JYMedtech、 Zhejiang Peptites Biotech、 Shengnuo Biotechnology、 Suzhou Tianma Pharmaceutical、 SINOPEP、 WuXi AppTec、 HYBIO Pharmaceutical ... |
This research report provides a comprehensive analysis of the GLP-1 Drug Peptide API market, focusing on the current trends, market dynamics, and future prospects. The report explores the global GLP-1 Drug Peptide API market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of GLP-1 Drug Peptide API, challenges faced by the industry, and potential opportunities for market players.
The global GLP-1 Drug Peptide API market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The GLP-1 Drug Peptide API market presents opportunities for various stakeholders, including Diabetes, Obesity. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in GLP-1 Drug Peptide API market. Additionally, the growing consumer demand present avenues for market expansion.
The global GLP-1 Drug Peptide API market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the GLP-1 Drug Peptide API market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the GLP-1 Drug Peptide API market.
Market Overview: The report provides a comprehensive overview of the GLP-1 Drug Peptide API market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Semaglutide, Liraglutide), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the GLP-1 Drug Peptide API market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the GLP-1 Drug Peptide API market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the GLP-1 Drug Peptide API market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the GLP-1 Drug Peptide API market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the GLP-1 Drug Peptide API market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the GLP-1 Drug Peptide API market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for GLP-1 Drug Peptide API, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the GLP-1 Drug Peptide API market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
GLP-1 Drug Peptide API market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Semaglutide
Liraglutide
Tilpotide
Market segment by Application
Diabetes
Obesity
Other
Global GLP-1 Drug Peptide API Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
CPC Scientific
Novo Nordisk
Teva Pharmaceutical Industries Ltd
JYMedtech
Zhejiang Peptites Biotech
Shengnuo Biotechnology
Suzhou Tianma Pharmaceutical
SINOPEP
WuXi AppTec
HYBIO Pharmaceutical
Outline of Major Chapters:
Chapter 1: Introduces the definition of GLP-1 Drug Peptide API, market overview.
Chapter 2: Global GLP-1 Drug Peptide API market size in revenue and volume.
Chapter 3: Detailed analysis of GLP-1 Drug Peptide API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of GLP-1 Drug Peptide API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global GLP-1 Drug Peptide API capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 GLP-1 Drug Peptide API Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global GLP-1 Drug Peptide API Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global GLP-1 Drug Peptide API Overall Market Size
2.1 Global GLP-1 Drug Peptide API Market Size: 2022 VS 2029
2.2 Global GLP-1 Drug Peptide API Revenue, Prospects & Forecasts: 2018-2029
2.3 Global GLP-1 Drug Peptide API Sales: 2018-2029
3 Company Landscape
3.1 Top GLP-1 Drug Peptide API Players in Global Market
3.2 Top Global GLP-1 Drug Peptide API Companies Ranked by Revenue
3.3 Global GLP-1 Drug Peptide API Revenue by Companies
3.4 Global GLP-1 Drug Peptide API Sales by Companies
3.5 Global GLP-1 Drug Peptide API Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 GLP-1 Drug Peptide API Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers GLP-1 Drug Peptide API Product Type
3.8 Tier 1, Tier 2 and Tier 3 GLP-1 Drug Peptide API Players in Global Market
3.8.1 List of Global Tier 1 GLP-1 Drug Peptide API Companies
3.8.2 List of Global Tier 2 and Tier 3 GLP-1 Drug Peptide API Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global GLP-1 Drug Peptide API Market Size Markets, 2022 & 2029
4.1.2 Semaglutide
4.1.3 Liraglutide
4.1.4 Tilpotide
4.2 By Type – Global GLP-1 Drug Peptide API Revenue & Forecasts
4.2.1 By Type – Global GLP-1 Drug Peptide API Revenue, 2018-2023
4.2.2 By Type – Global GLP-1 Drug Peptide API Revenue, 2024-2029
4.2.3 By Type – Global GLP-1 Drug Peptide API Revenue Market Share, 2018-2029
4.3 By Type – Global GLP-1 Drug Peptide API Sales & Forecasts
4.3.1 By Type – Global GLP-1 Drug Peptide API Sales, 2018-2023
4.3.2 By Type – Global GLP-1 Drug Peptide API Sales, 2024-2029
4.3.3 By Type – Global GLP-1 Drug Peptide API Sales Market Share, 2018-2029
4.4 By Type – Global GLP-1 Drug Peptide API Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global GLP-1 Drug Peptide API Market Size, 2022 & 2029
5.1.2 Diabetes
5.1.3 Obesity
5.1.4 Other
5.2 By Application – Global GLP-1 Drug Peptide API Revenue & Forecasts
5.2.1 By Application – Global GLP-1 Drug Peptide API Revenue, 2018-2023
5.2.2 By Application – Global GLP-1 Drug Peptide API Revenue, 2024-2029
5.2.3 By Application – Global GLP-1 Drug Peptide API Revenue Market Share, 2018-2029
5.3 By Application – Global GLP-1 Drug Peptide API Sales & Forecasts
5.3.1 By Application – Global GLP-1 Drug Peptide API Sales, 2018-2023
5.3.2 By Application – Global GLP-1 Drug Peptide API Sales, 2024-2029
5.3.3 By Application – Global GLP-1 Drug Peptide API Sales Market Share, 2018-2029
5.4 By Application – Global GLP-1 Drug Peptide API Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global GLP-1 Drug Peptide API Market Size, 2022 & 2029
6.2 By Region – Global GLP-1 Drug Peptide API Revenue & Forecasts
6.2.1 By Region – Global GLP-1 Drug Peptide API Revenue, 2018-2023
6.2.2 By Region – Global GLP-1 Drug Peptide API Revenue, 2024-2029
6.2.3 By Region – Global GLP-1 Drug Peptide API Revenue Market Share, 2018-2029
6.3 By Region – Global GLP-1 Drug Peptide API Sales & Forecasts
6.3.1 By Region – Global GLP-1 Drug Peptide API Sales, 2018-2023
6.3.2 By Region – Global GLP-1 Drug Peptide API Sales, 2024-2029
6.3.3 By Region – Global GLP-1 Drug Peptide API Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America GLP-1 Drug Peptide API Revenue, 2018-2029
6.4.2 By Country – North America GLP-1 Drug Peptide API Sales, 2018-2029
6.4.3 US GLP-1 Drug Peptide API Market Size, 2018-2029
6.4.4 Canada GLP-1 Drug Peptide API Market Size, 2018-2029
6.4.5 Mexico GLP-1 Drug Peptide API Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe GLP-1 Drug Peptide API Revenue, 2018-2029
6.5.2 By Country – Europe GLP-1 Drug Peptide API Sales, 2018-2029
6.5.3 Germany GLP-1 Drug Peptide API Market Size, 2018-2029
6.5.4 France GLP-1 Drug Peptide API Market Size, 2018-2029
6.5.5 U.K. GLP-1 Drug Peptide API Market Size, 2018-2029
6.5.6 Italy GLP-1 Drug Peptide API Market Size, 2018-2029
6.5.7 Russia GLP-1 Drug Peptide API Market Size, 2018-2029
6.5.8 Nordic Countries GLP-1 Drug Peptide API Market Size, 2018-2029
6.5.9 Benelux GLP-1 Drug Peptide API Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia GLP-1 Drug Peptide API Revenue, 2018-2029
6.6.2 By Region – Asia GLP-1 Drug Peptide API Sales, 2018-2029
6.6.3 China GLP-1 Drug Peptide API Market Size, 2018-2029
6.6.4 Japan GLP-1 Drug Peptide API Market Size, 2018-2029
6.6.5 South Korea GLP-1 Drug Peptide API Market Size, 2018-2029
6.6.6 Southeast Asia GLP-1 Drug Peptide API Market Size, 2018-2029
6.6.7 India GLP-1 Drug Peptide API Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America GLP-1 Drug Peptide API Revenue, 2018-2029
6.7.2 By Country – South America GLP-1 Drug Peptide API Sales, 2018-2029
6.7.3 Brazil GLP-1 Drug Peptide API Market Size, 2018-2029
6.7.4 Argentina GLP-1 Drug Peptide API Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa GLP-1 Drug Peptide API Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa GLP-1 Drug Peptide API Sales, 2018-2029
6.8.3 Turkey GLP-1 Drug Peptide API Market Size, 2018-2029
6.8.4 Israel GLP-1 Drug Peptide API Market Size, 2018-2029
6.8.5 Saudi Arabia GLP-1 Drug Peptide API Market Size, 2018-2029
6.8.6 UAE GLP-1 Drug Peptide API Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 CPC Scientific
7.1.1 CPC Scientific Company Summary
7.1.2 CPC Scientific Business Overview
7.1.3 CPC Scientific GLP-1 Drug Peptide API Major Product Offerings
7.1.4 CPC Scientific GLP-1 Drug Peptide API Sales and Revenue in Global (2018-2023)
7.1.5 CPC Scientific Key News & Latest Developments
7.2 Novo Nordisk
7.2.1 Novo Nordisk Company Summary
7.2.2 Novo Nordisk Business Overview
7.2.3 Novo Nordisk GLP-1 Drug Peptide API Major Product Offerings
7.2.4 Novo Nordisk GLP-1 Drug Peptide API Sales and Revenue in Global (2018-2023)
7.2.5 Novo Nordisk Key News & Latest Developments
7.3 Teva Pharmaceutical Industries Ltd
7.3.1 Teva Pharmaceutical Industries Ltd Company Summary
7.3.2 Teva Pharmaceutical Industries Ltd Business Overview
7.3.3 Teva Pharmaceutical Industries Ltd GLP-1 Drug Peptide API Major Product Offerings
7.3.4 Teva Pharmaceutical Industries Ltd GLP-1 Drug Peptide API Sales and Revenue in Global (2018-2023)
7.3.5 Teva Pharmaceutical Industries Ltd Key News & Latest Developments
7.4 JYMedtech
7.4.1 JYMedtech Company Summary
7.4.2 JYMedtech Business Overview
7.4.3 JYMedtech GLP-1 Drug Peptide API Major Product Offerings
7.4.4 JYMedtech GLP-1 Drug Peptide API Sales and Revenue in Global (2018-2023)
7.4.5 JYMedtech Key News & Latest Developments
7.5 Zhejiang Peptites Biotech
7.5.1 Zhejiang Peptites Biotech Company Summary
7.5.2 Zhejiang Peptites Biotech Business Overview
7.5.3 Zhejiang Peptites Biotech GLP-1 Drug Peptide API Major Product Offerings
7.5.4 Zhejiang Peptites Biotech GLP-1 Drug Peptide API Sales and Revenue in Global (2018-2023)
7.5.5 Zhejiang Peptites Biotech Key News & Latest Developments
7.6 Shengnuo Biotechnology
7.6.1 Shengnuo Biotechnology Company Summary
7.6.2 Shengnuo Biotechnology Business Overview
7.6.3 Shengnuo Biotechnology GLP-1 Drug Peptide API Major Product Offerings
7.6.4 Shengnuo Biotechnology GLP-1 Drug Peptide API Sales and Revenue in Global (2018-2023)
7.6.5 Shengnuo Biotechnology Key News & Latest Developments
7.7 Suzhou Tianma Pharmaceutical
7.7.1 Suzhou Tianma Pharmaceutical Company Summary
7.7.2 Suzhou Tianma Pharmaceutical Business Overview
7.7.3 Suzhou Tianma Pharmaceutical GLP-1 Drug Peptide API Major Product Offerings
7.7.4 Suzhou Tianma Pharmaceutical GLP-1 Drug Peptide API Sales and Revenue in Global (2018-2023)
7.7.5 Suzhou Tianma Pharmaceutical Key News & Latest Developments
7.8 SINOPEP
7.8.1 SINOPEP Company Summary
7.8.2 SINOPEP Business Overview
7.8.3 SINOPEP GLP-1 Drug Peptide API Major Product Offerings
7.8.4 SINOPEP GLP-1 Drug Peptide API Sales and Revenue in Global (2018-2023)
7.8.5 SINOPEP Key News & Latest Developments
7.9 WuXi AppTec
7.9.1 WuXi AppTec Company Summary
7.9.2 WuXi AppTec Business Overview
7.9.3 WuXi AppTec GLP-1 Drug Peptide API Major Product Offerings
7.9.4 WuXi AppTec GLP-1 Drug Peptide API Sales and Revenue in Global (2018-2023)
7.9.5 WuXi AppTec Key News & Latest Developments
7.10 HYBIO Pharmaceutical
7.10.1 HYBIO Pharmaceutical Company Summary
7.10.2 HYBIO Pharmaceutical Business Overview
7.10.3 HYBIO Pharmaceutical GLP-1 Drug Peptide API Major Product Offerings
7.10.4 HYBIO Pharmaceutical GLP-1 Drug Peptide API Sales and Revenue in Global (2018-2023)
7.10.5 HYBIO Pharmaceutical Key News & Latest Developments
8 Global GLP-1 Drug Peptide API Production Capacity, Analysis
8.1 Global GLP-1 Drug Peptide API Production Capacity, 2018-2029
8.2 GLP-1 Drug Peptide API Production Capacity of Key Manufacturers in Global Market
8.3 Global GLP-1 Drug Peptide API Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 GLP-1 Drug Peptide API Supply Chain Analysis
10.1 GLP-1 Drug Peptide API Industry Value Chain
10.2 GLP-1 Drug Peptide API Upstream Market
10.3 GLP-1 Drug Peptide API Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 GLP-1 Drug Peptide API Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
